Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	1149 treatment-naïve people; mixed HCV genotype	Proportion of people withdrawing from the study because of an adverse effect 32/453 (7%) with peginterferon alfa-2a plus ribavirin 13/224 (6%) with peginterferon alfa-2a plus placebo	Significance not assessed
RCT 3-armed trial	1149 treatment-naïve people; mixed HCV genotype	Proportion of people reporting depression as an adverse effect 100/453 (22%) with peginterferon alfa-2a plus ribavirin 45/224 (20%) with peginterferon alfa-2a plus placebo	Significance not assessed
RCT	201 treatment-naïve Japanese people with HCV genotype 1	Proportion of people withdrawing from treatment due to adverse effects 7/99 (7%) with peginterferon alfa-2a plus ribavirin 12/101 (12%) with peginterferon alfa-2a plus placebo	Significance not assessed
RCT	201 treatment-naïve Japanese people with HCV genotype 1	Proportion of people reporting a serious adverse effect 11/99 (11%) with peginterferon alfa-2a plus ribavirin 13/101 (13%) with peginterferon alfa-2a plus placebo	Significance not assessed